← back to search

Belén San Antonio

Eli Lilly (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, Lung Cancer Research Studies, and Lung Cancer Diagnosis and Treatment.
h-index
16
citations
2,081
works
49
NIH funding
primary concept
Medicine
email

Recent publications

Overall survival with abemaciclib in early breast cancer
Annals of Oncology 2025cited by 20position: middledoi
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology 2024cited by 195position: middledoi
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Annals of Oncology 2023cited by 21position: middledoi
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology 2022cited by 546position: middledoi
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Annals of Oncology 2022cited by 122position: middledoi
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology 2021cited by 374position: middledoi
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Breast Cancer Research and Treatment 2021cited by 55position: middledoi
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Journal of Clinical Oncology 2016cited by 432position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Priya Rastogi · UPMC Hillman Cancer Center5 papers (2022–2025)Matthew P. Goetz · Mayo Clinic5 papers (2021–2025)Ashwin Shahir · Eli Lilly (United States)5 papers (2022–2025)Patrick Neven · European Organisation for Research and Treatment of Cancer4 papers (2022–2025)Chiun‐Sheng Huang · National Taiwan University Hospital4 papers (2022–2025)Stephen Johnston · Royal Marsden NHS Foundation Trust4 papers (2022–2024)Ran Wei · Weifang Medical University4 papers (2022–2025)Elżbieta Senkus · European Institute of Oncology4 papers (2022–2025)Jens Huober · University Hospital Ulm4 papers (2022–2025)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2022–2024)Erika Hamilton · Duke Medical Center3 papers (2023–2025)Nadia Harbeck · Universität Bayern3 papers (2022–2024)Laura Testa · D’Or Institute for Research and Education3 papers (2022–2025)Javier Cortés · Universidade Nova de Lisboa3 papers (2023–2025)Joyce O’Shaughnessy · Baylor University Medical Center3 papers (2022–2024)Mario Campone · Centre de Recherche en Cancérologie de Lyon3 papers (2021–2022)Masakazu Toi · Universal Scientific Education and Research Network3 papers (2021–2022)F Boyle · The University of Sydney2 papers (2022–2025)A. Tryakin · City Clinical Hospital2 papers (2023–2024)Nadia Chouaki · Hôpital américain de paris2 papers (2016–2021)